Of note, the possible contribution of lowered expression of several of these genes in human tumors is already proven, like PAFAH1B1 in non-small cell lung cancer, SMARCC1 in pancreatic cancer and NKN2 in myeloproliferative neoplasm (MPN) precursors (Lo et al., 2012; Iwagami et al., 2013; Mehrotra et al., 2013). Here, SMARCC1 is linked to myeloproliferative disorder.